Analytical Data
-
Gene name
P2RX1
- Application
-
Alternative Names
P2X1; P2X Purinoceptor 1; ATP receptor; Purinergic receptor
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P51576
-
Expression Region
Thr57~Gly338
-
Molecular Weight
36kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
P2RX1, or purinergic receptor P2X, ionotropic 1, is a member of the P2X receptor family, which are ATP-gated ion channels known to play crucial roles in various physiological and pathological processes. Research on P2RX1 is particularly significant due to its involvement in pain transmission, inflammation, and tissue injury responses. Increased expression or activity of P2RX1 has been implicated in several diseases, including chronic pain conditions and certain neurological disorders. As a receptor that mediates neurotransmission in both the central and peripheral nervous systems, P2RX1 is of great interest for drug development, with potential therapeutic strategies targeting its signaling pathways to alleviate pain or modulate inflammatory responses. The production and characterization of recombinant P2RX1 proteins provide valuable insights into its structure-function relationships, ligand-binding properties, and downstream signaling mechanisms. Utilizing techniques such as site-directed mutagenesis, crystallography, and electrophysiology, researchers aim to elucidate how variations in P2RX1 affect its pharmacological profiles. These studies not only enhance our fundamental understanding of P2RX1 biology but also pave the way for novel therapeutic approaches in treating conditions associated with P2RX1 dysregulation. Given the increasing recognition of purinergic signaling in health and disease, the investigation of P2RX1 as a potential therapeutic target remains a vibrant and evolving area of research.
